| NCT05951205 | Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype | NOT_YET_RECRUITING | PHASE3 | 2027-07-31 | 2033-12-31 | 2033-12-31 |
| NCT07204275 | A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | NOT_YET_RECRUITING | PHASE2, PHASE3 | 2025-10-06 | 2028-12-29 | 2028-12-29 |
| NCT07161037 | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants | RECRUITING | PHASE2 | 2025-09-26 | 2027-12-31 | 2027-07-22 |
| NCT07074327 | Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants | RECRUITING | PHASE1 | 2025-07-11 | 2026-07-04 | 2026-06-29 |
| NCT07022119 | A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants | RECRUITING | PHASE1 | 2025-06-12 | 2025-09-29 | 2025-09-29 |
| NCT07010406 | A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations | COMPLETED | PHASE1 | 2025-06-06 | 2025-08-19 | 2025-08-19 |
| NCT06926621 | A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I | ENROLLING_BY_INVITATION | PHASE2 | 2025-04-28 | 2028-07-24 | 2028-07-24 |
| NCT06861413 | A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation | COMPLETED | PHASE1 | 2025-04-01 | 2025-05-05 | 2025-05-05 |
| NCT06832410 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | RECRUITING | PHASE3 | 2025-03-31 | 2027-09-17 | 2026-09-17 |
| NCT06887959 | A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries | RECRUITING | PHASE4 | 2025-03-27 | 2026-01-15 | 2026-01-01 |
| NCT06886269 | A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose | COMPLETED | PHASE1 | 2025-03-21 | 2025-05-17 | 2025-05-17 |
| NCT06887972 | A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries | RECRUITING | PHASE4 | 2025-03-21 | 2026-01-01 | 2025-12-18 |
| NCT06834009 | A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists | COMPLETED | PHASE1 | 2025-03-10 | 2025-04-24 | 2025-04-24 |
| NCT06820307 | Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants | COMPLETED | PHASE1 | 2025-02-25 | 2025-04-29 | 2025-04-29 |
| NCT06794996 | Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease | RECRUITING | PHASE2 | 2025-02-04 | 2026-12-30 | 2026-12-30 |
| NCT06696443 | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | ENROLLING_BY_INVITATION | PHASE3 | 2024-12-18 | 2027-01-25 | 2027-01-25 |
| NCT06460506 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-11-21 | 2027-09-30 | 2027-09-30 |
| NCT06619847 | A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy | COMPLETED | PHASE2 | 2024-10-29 | 2025-05-27 | 2025-05-27 |
| NCT06619860 | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy | RECRUITING | PHASE2 | 2024-10-18 | 2026-05-30 | 2026-04-30 |
| NCT06628908 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | RECRUITING | PHASE3 | 2024-10-01 | 2027-05-31 | 2027-05-31 |
| NCT06615570 | A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants | COMPLETED | PHASE1 | 2024-09-30 | 2025-07-21 | 2025-07-21 |
| NCT06529796 | Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment | COMPLETED | PHASE1 | 2024-08-02 | 2024-12-20 | 2024-12-20 |
| NCT06523595 | Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults | COMPLETED | PHASE1 | 2024-07-31 | 2024-12-31 | 2024-12-31 |
| NCT06508762 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 | COMPLETED | PHASE1 | 2024-07-26 | 2024-09-10 | 2024-09-10 |
| NCT06420765 | A Microneurography Study of NaV1.8 Inhibition in Healthy Adults | COMPLETED | PHASE1 | 2024-05-21 | 2025-04-04 | 2025-03-22 |
| NCT06394167 | A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults | COMPLETED | PHASE1 | 2024-05-09 | 2025-02-18 | 2025-02-18 |
| NCT06392659 | A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults | COMPLETED | PHASE1 | 2024-05-02 | 2024-07-02 | 2024-07-02 |
| NCT06345755 | A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants | COMPLETED | PHASE1 | 2024-04-17 | 2025-06-13 | 2025-01-27 |
| NCT06312787 | A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation | COMPLETED | PHASE1 | 2024-04-02 | 2024-05-04 | 2024-05-04 |
| NCT06336096 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine | COMPLETED | PHASE1 | 2024-03-28 | 2024-06-19 | 2024-06-19 |
| NCT06299696 | A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists | COMPLETED | PHASE1 | 2024-03-26 | 2024-04-16 | 2024-04-16 |
| NCT06299709 | A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA) | COMPLETED | PHASE1 | 2024-03-13 | 2024-05-23 | 2024-05-23 |
| NCT06185764 | A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | RECRUITING | PHASE1, PHASE2 | 2024-02-20 | 2026-12-31 | 2026-12-31 |
| NCT06226454 | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993 | COMPLETED | PHASE1 | 2024-01-04 | 2024-06-12 | 2024-06-12 |
| NCT06176196 | Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR) | COMPLETED | PHASE2 | 2023-12-13 | 2024-10-16 | 2024-10-02 |
| NCT06154447 | Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis | RECRUITING | PHASE1 | 2023-12-12 | 2026-04-23 | 2026-04-23 |
| NCT05844449 | Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older | ENROLLING_BY_INVITATION | PHASE3 | 2023-08-11 | 2029-07-30 | 2029-07-30 |
| NCT05955872 | A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147 | COMPLETED | PHASE1 | 2023-07-19 | 2023-09-02 | 2023-09-02 |
| NCT05882357 | Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age | COMPLETED | PHASE3 | 2023-06-27 | 2025-09-04 | 2025-09-04 |
| NCT05865171 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment | COMPLETED | PHASE1 | 2023-06-12 | 2024-06-12 | 2024-06-12 |
| NCT05791201 | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-05-16 | 2026-05-29 | 2026-05-29 |
| NCT05866055 | A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults | COMPLETED | PHASE1 | 2023-05-10 | 2024-04-04 | 2024-04-04 |
| NCT05851157 | A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548 | COMPLETED | PHASE1 | 2023-05-03 | 2023-11-08 | 2023-10-30 |
| NCT05867147 | An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants | COMPLETED | PHASE1 | 2023-04-26 | 2023-06-14 | 2023-06-14 |
| NCT05818852 | A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants | COMPLETED | PHASE1 | 2023-04-12 | 2023-06-28 | 2023-06-12 |
| NCT05668741 | A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) | RECRUITING | PHASE1, PHASE2 | 2023-02-27 | 2027-05-12 | 2026-12-23 |
| NCT05704556 | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment | COMPLETED | PHASE1 | 2023-02-27 | 2024-03-30 | 2024-03-30 |
| NCT05643495 | A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype | TERMINATED | PHASE2 | 2023-02-23 | 2024-08-19 | 2024-08-19 |
| NCT05727800 | A Phase 1, First-in-human Study of VX-668 | COMPLETED | PHASE1 | 2023-02-08 | 2024-02-13 | 2023-09-12 |
| NCT05661734 | A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain | COMPLETED | PHASE3 | 2023-01-09 | 2023-12-12 | 2023-12-12 |
| NCT05660538 | Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) | COMPLETED | PHASE2 | 2022-12-20 | 2023-10-25 | 2023-10-12 |
| NCT05635110 | Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants | COMPLETED | PHASE1 | 2022-12-15 | 2023-06-08 | 2023-06-08 |
| NCT05653323 | A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants | COMPLETED | PHASE1 | 2022-12-14 | 2023-09-12 | 2023-09-12 |
| NCT05331183 | Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-11-23 | 2027-04-06 | 2027-04-06 |
| NCT05444257 | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-11-08 | 2026-10-30 | 2026-10-30 |
| NCT05560464 | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment | COMPLETED | PHASE1 | 2022-10-14 | 2023-07-24 | 2023-07-24 |
| NCT05579431 | A Phase 1, First-in-human Study of VX-634 | COMPLETED | PHASE1 | 2022-10-13 | 2023-11-13 | 2023-05-24 |
| NCT05558410 | Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty | COMPLETED | PHASE3 | 2022-10-10 | 2023-09-11 | 2023-08-25 |
| NCT05553366 | Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | COMPLETED | PHASE3 | 2022-10-03 | 2023-12-15 | 2023-12-15 |
| NCT05541471 | A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin | COMPLETED | PHASE1 | 2022-09-22 | 2023-04-28 | 2023-04-16 |
| NCT05518734 | A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants | COMPLETED | PHASE1 | 2022-09-17 | 2023-03-07 | 2023-03-07 |
| NCT05535959 | A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor | COMPLETED | PHASE1 | 2022-09-15 | 2022-11-09 | 2022-11-09 |
| NCT05477563 | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | RECRUITING | PHASE3 | 2022-08-02 | 2027-06-09 | 2027-06-09 |
| NCT05437120 | Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment | COMPLETED | PHASE1 | 2022-07-22 | 2023-03-16 | 2023-03-16 |
| NCT05455502 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548 | COMPLETED | PHASE1 | 2022-07-13 | 2022-09-17 | 2022-09-17 |
| NCT05422222 | Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age | RECRUITING | PHASE3 | 2022-06-21 | 2030-06-30 | 2030-06-30 |
| NCT05418712 | A Microneurography (MNG) Study of VX-150 in Healthy Participants | COMPLETED | PHASE1 | 2022-06-16 | 2022-09-23 | 2022-09-14 |
| NCT05274269 | Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation | COMPLETED | PHASE3 | 2022-05-09 | 2023-07-05 | 2023-07-05 |
| NCT05356195 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | RECRUITING | PHASE3 | 2022-05-03 | 2026-05 | 2026-05 |
| NCT05329649 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | RECRUITING | PHASE3 | 2022-05-02 | 2026-05 | 2026-05 |
| NCT05347394 | A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants | COMPLETED | PHASE1 | 2022-04-08 | 2023-04-14 | 2023-04-14 |
| NCT05324410 | A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants | COMPLETED | PHASE1 | 2022-04-07 | 2022-11-07 | 2022-11-07 |
| NCT05312879 | Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease | RECRUITING | PHASE2, PHASE3 | 2022-03-30 | 2026-06-30 | 2026-05-31 |
| NCT05153317 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-01-17 | 2026-04-30 | 2026-04-30 |
| NCT05111145 | A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF) | COMPLETED | PHASE3 | 2022-01-14 | 2022-12-20 | 2022-12-20 |
| NCT05076149 | A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation | COMPLETED | PHASE3 | 2021-10-27 | 2023-11-30 | 2023-05-18 |
| NCT04969224 | A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF) | COMPLETED | PHASE3 | 2021-10-12 | 2022-07-26 | 2022-07-26 |
| NCT05033080 | A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) | COMPLETED | PHASE3 | 2021-09-14 | 2023-11-21 | 2023-05-12 |
| NCT05034952 | A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty | COMPLETED | PHASE2 | 2021-08-30 | 2021-12-21 | 2021-12-05 |
| NCT04977336 | A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | COMPLETED | PHASE2 | 2021-07-19 | 2022-03-04 | 2022-02-17 |
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | RECRUITING | PHASE3 | 2021-03-29 | 2030-06-30 | 2027-06-30 |
| NCT04208529 | A Long-term Follow-up Study in Participants Who Received CTX001 | ENROLLING_BY_INVITATION | PHASE3 | 2021-01-20 | 2039-09-30 | 2039-09-30 |
| NCT04599465 | A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) | COMPLETED | PHASE3 | 2021-01-15 | 2022-07-14 | 2022-07-14 |
| NCT04545515 | A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes | COMPLETED | PHASE3 | 2021-01-11 | 2023-03-24 | 2023-03-24 |
| NCT04537793 | Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years | COMPLETED | PHASE3 | 2020-11-19 | 2022-06-03 | 2022-06-03 |
| NCT04474197 | Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype | COMPLETED | PHASE2 | 2020-07-24 | 2021-05-04 | 2021-05-04 |
| NCT04353817 | A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes | COMPLETED | PHASE3 | 2020-06-19 | 2021-05-17 | 2021-05-17 |
| NCT04340362 | Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis | COMPLETED | PHASE2 | 2020-06-08 | 2021-12-09 | 2021-11-11 |
| NCT04362761 | A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy | COMPLETED | PHASE3 | 2020-05-04 | 2022-12-21 | 2022-12-21 |
| NCT04235140 | Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation | COMPLETED | PHASE3 | 2020-02-24 | 2023-08-22 | 2023-08-22 |
| NCT04183790 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older | COMPLETED | PHASE3 | 2020-02-17 | 2024-02-24 | 2024-02-24 |
| NCT04167345 | Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype | TERMINATED | PHASE2 | 2020-01-13 | 2020-11-14 | 2020-11-14 |
| NCT04058366 | Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | COMPLETED | PHASE3 | 2019-12-05 | 2022-12-16 | 2022-12-16 |
| NCT04105972 | A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del | COMPLETED | PHASE3 | 2019-10-03 | 2020-07-24 | 2020-07-24 |
| NCT04058353 | A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) | COMPLETED | PHASE3 | 2019-08-28 | 2020-06-12 | 2020-06-12 |
| NCT04043806 | A Study Evaluating the Long-term Safety of VX-445 Combination Therapy | COMPLETED | PHASE3 | 2019-08-09 | 2022-12-14 | 2022-12-14 |
| NCT03912233 | A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis | COMPLETED | PHASE2 | 2019-04-30 | 2019-12-10 | 2019-12-10 |
| NCT03911713 | A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis | COMPLETED | PHASE2 | 2019-04-17 | 2020-08-20 | 2020-08-20 |
| NCT03764072 | A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy | COMPLETED | PHASE2 | 2018-12-12 | 2019-01-25 | 2019-01-17 |
| NCT03745287 | A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease | COMPLETED | PHASE2, PHASE3 | 2018-11-27 | 2025-07-07 | 2025-07-07 |
| NCT03525574 | A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | COMPLETED | PHASE3 | 2018-10-09 | 2023-01-09 | 2023-01-09 |
| NCT03691779 | Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age | COMPLETED | PHASE3 | 2018-10-02 | 2020-08-07 | 2020-08-07 |
| NCT03655678 | A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2018-09-14 | 2025-12-08 | 2025-12-08 |
| NCT03601637 | Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del | COMPLETED | PHASE3 | 2018-09-07 | 2021-10-29 | 2021-10-29 |
| NCT03625466 | A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del | COMPLETED | PHASE2 | 2018-08-10 | 2021-10-07 | 2020-10-09 |
| NCT03525548 | A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) | COMPLETED | PHASE3 | 2018-08-03 | 2018-12-28 | 2018-12-28 |
| NCT03633526 | Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age | TERMINATED | PHASE3 | 2018-08-03 | 2019-01-18 | 2019-01-18 |
| NCT03447262 | A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy | TERMINATED | PHASE3 | 2018-07-13 | 2020-09-09 | 2020-09-09 |
| NCT03525444 | A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) | COMPLETED | PHASE3 | 2018-06-15 | 2019-04-24 | 2019-04-24 |
| NCT03559062 | A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis | COMPLETED | PHASE3 | 2018-05-17 | 2018-12-21 | 2018-12-21 |
| NCT03460990 | A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F) | COMPLETED | PHASE3 | 2018-05-01 | 2018-10-08 | 2018-09-26 |
| NCT03537651 | A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation | COMPLETED | PHASE3 | 2018-04-25 | 2023-09-29 | 2020-10-28 |
| NCT03768089 | Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis | COMPLETED | PHASE1, PHASE2 | 2018-03-20 | 2019-05-03 | 2019-05-03 |
| NCT03447249 | A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) | COMPLETED | PHASE3 | 2018-03-07 | 2019-02-05 | 2019-02-05 |
| NCT03304522 | A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy | COMPLETED | PHASE2 | 2017-09-20 | 2018-11-08 | 2018-10-12 |
| NCT03277196 | A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation | COMPLETED | PHASE3 | 2017-08-16 | 2023-10-02 | 2023-10-02 |
| NCT03224351 | A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis | COMPLETED | PHASE2 | 2017-08-08 | 2018-02-28 | 2018-02-28 |
| NCT03068312 | A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation | COMPLETED | PHASE3 | 2017-07-18 | 2018-12-18 | 2018-12-18 |
| NCT03206749 | A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy | COMPLETED | PHASE2 | 2017-06-29 | 2017-12-08 | 2017-12-01 |
| NCT03150719 | A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF) | COMPLETED | PHASE3 | 2017-05-24 | 2018-08-09 | 2018-08-09 |
| NCT03125395 | A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | COMPLETED | PHASE3 | 2017-05-12 | 2019-07-17 | 2019-07-17 |
| NCT03061331 | Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation | COMPLETED | PHASE2 | 2017-01-31 | 2017-10-04 | 2017-09-06 |
| NCT03227471 | A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis | COMPLETED | PHASE1, PHASE2 | 2017-01-23 | 2018-03-27 | 2018-03-27 |
| NCT02971839 | Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations | TERMINATED | PHASE2 | 2016-12 | 2017-08 | 2017-08 |
| NCT02951195 | A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis | COMPLETED | PHASE2 | 2016-11 | 2018-01 | 2018-01 |
| NCT02953314 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) | COMPLETED | PHASE3 | 2016-11 | 2018-09 | 2018-09 |
| NCT03029455 | A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis | COMPLETED | PHASE1 | 2016-11 | 2017-08 | 2017-08 |
| NCT02951182 | A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis | COMPLETED | PHASE2 | 2016-10 | 2017-08 | 2017-08 |
| NCT02730208 | A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation | COMPLETED | PHASE2 | 2016-09 | 2018-07 | 2018-07 |
| NCT02875366 | A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation | COMPLETED | PHASE4 | 2016-09 | 2017-10 | 2017-09 |
| NCT03486236 | A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects | COMPLETED | PHASE1 | 2016-07-20 | 2016-09-14 | 2016-09-14 |
| NCT02669849 | Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury | TERMINATED | PHASE2, PHASE3 | 2016-07 | 2018-11 | 2018-11 |
| NCT02725567 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation | COMPLETED | PHASE3 | 2016-06-02 | 2022-06-28 | 2022-06-28 |
| NCT02823470 | A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation | TERMINATED | PHASE4 | 2016-06 | 2017-08 | 2017-08 |
| NCT02742519 | A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation | TERMINATED | PHASE3 | 2016-05 | 2017-08 | 2017-08 |
| NCT02797132 | Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del | COMPLETED | PHASE3 | 2016-05 | 2017-09 | 2017-09 |
| NCT02508207 | A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | COMPLETED | PHASE2 | 2016-02 | 2017-06 | 2017-06 |
| NCT02660424 | A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee | COMPLETED | PHASE2 | 2015-12 | 2016-09 | 2016-08 |
| NCT02565914 | A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation | COMPLETED | PHASE3 | 2015-08 | 2022-12-05 | 2019-05 |
| NCT02544451 | Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor | COMPLETED | PHASE3 | 2015-08 | 2020-04 | 2018-08 |
| NCT02516410 | A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation | COMPLETED | PHASE3 | 2015-08 | 2016-06-07 | 2016-06-07 |
| NCT02514473 | A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation | COMPLETED | PHASE3 | 2015-07 | 2016-09 | 2016-09 |
| NCT02412111 | A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor | COMPLETED | PHASE3 | 2015-06 | 2017-09 | 2017-09 |
| NCT02392234 | A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation | COMPLETED | PHASE3 | 2015-03 | 2017-02 | 2017-02 |
| NCT02390219 | Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease | COMPLETED | PHASE3 | 2015-03 | 2016-10 | 2016-10 |
| NCT02347657 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor | COMPLETED | PHASE3 | 2015-01 | 2017-01-20 | 2017-01-20 |
| NCT02070744 | Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion | COMPLETED | PHASE2 | 2014-03 | 2016-05-27 | 2016-05-27 |
| NCT02015507 | An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor | COMPLETED | PHASE1 | 2014-01 | 2014-02 | 2014-02 |
| NCT01946412 | Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation | COMPLETED | PHASE3 | 2013-12 | 2015-12 | 2015-12 |
| NCT01931839 | A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis | COMPLETED | PHASE3 | 2013-10 | 2016-04 | 2016-04 |
| NCT01897233 | Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | COMPLETED | PHASE3 | 2013-07 | 2015-10 | 2015-10 |
| NCT01899105 | A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor | COMPLETED | PHASE1 | 2013-07 | 2013-08 | 2013-08 |
| NCT01842451 | A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C | COMPLETED | PHASE2 | 2013-06 | 2014-05 | 2014-05 |
| NCT01910415 | Phase 1, QT/QTC Interval Study in Healthy Subjects | COMPLETED | PHASE1 | 2013-06 | 2014-03 | 2014-03 |
| NCT01888393 | Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects | COMPLETED | PHASE1 | 2013-06 | 2013-11 | 2013-11 |
| NCT01886209 | Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects | COMPLETED | PHASE1 | 2013-06 | 2013-08 | 2013-08 |
| NCT01807923 | A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation | COMPLETED | PHASE3 | 2013-05 | 2014-04 | 2014-04 |
| NCT01807949 | A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation | COMPLETED | PHASE3 | 2013-04 | 2014-04 | 2014-04 |
| NCT01830985 | A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis | COMPLETED | PHASE2, PHASE3 | 2013-04 | 2014-07 | 2014-07 |
| NCT01707290 | Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation | COMPLETED | PHASE3 | 2013-02 | 2016-04 | 2016-04 |
| NCT01701063 | An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus | TERMINATED | PHASE1, PHASE2 | 2013-01 | 2015-04 | 2015-04 |
| NCT01705145 | Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation | COMPLETED | PHASE3 | 2013-01 | 2014-03 | 2014-03 |
| NCT01754935 | A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor | COMPLETED | PHASE2 | 2013-01 | 2014-02 | 2014-01 |
| NCT01768663 | A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects | COMPLETED | PHASE1 | 2013-01 | | 2013-09 |
| NCT01726946 | A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C | COMPLETED | PHASE2 | 2012-11 | 2014-02 | 2014-02 |
| NCT01685801 | Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function | COMPLETED | PHASE2 | 2012-09 | 2014-04 | 2014-04 |
| NCT01614457 | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) | COMPLETED | PHASE3 | 2012-07 | 2013-10 | 2013-10 |
| NCT01614470 | Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation | COMPLETED | PHASE3 | 2012-07 | 2013-10 | 2013-10 |
| NCT01581138 | VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C | COMPLETED | PHASE2 | 2012-07 | 2013-12 | 2013-06 |
| NCT01590459 | 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate | COMPLETED | PHASE2 | 2012-04 | 2014-07 | 2014-07 |
| NCT01561807 | A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus | COMPLETED | PHASE2 | 2012-03 | | 2012-10 |
| NCT01531673 | Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation | COMPLETED | PHASE2 | 2012-02 | 2014-03 | 2014-03 |
| NCT01467505 | An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients | TERMINATED | PHASE2 | 2012-02 | 2014-04 | 2014-04 |
| NCT01516918 | A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis | COMPLETED | PHASE2 | 2012-02 | 2013-12 | 2013-09 |
| NCT01467492 | Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C | TERMINATED | PHASE4 | 2012-01 | 2014-05 | 2014-05 |
| NCT01511432 | A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects | COMPLETED | PHASE1 | 2012-01 | 2012-07 | 2012-06 |
| NCT01501383 | A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy | TERMINATED | PHASE2 | 2011-12 | | 2013-08 |
| NCT01467479 | A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV) | TERMINATED | PHASE3 | 2011-12 | 2014-02 | 2014-02 |
| NCT01459913 | Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype | TERMINATED | PHASE3 | 2011-11 | 2014-01 | 2014-01 |
| NCT01262352 | Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation | COMPLETED | PHASE2 | 2011-01 | 2011-11 | 2011-11 |
| NCT01275599 | Drug-Drug Interaction Study Between Telaprevir and Buprenorphine | COMPLETED | PHASE1 | 2011-01 | | 2011-04 |
| NCT01225211 | Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation | COMPLETED | PHASE2 | 2010-10 | 2014-04 | 2014-04 |
| NCT01161537 | Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation | COMPLETED | PHASE2 | 2010-10 | 2013-02 | 2013-02 |
| NCT01216046 | Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects | COMPLETED | PHASE1 | 2010-10 | 2011-05 | 2011-05 |
| NCT01208285 | Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects | COMPLETED | PHASE1 | 2010-09 | 2010-12 | 2010-12 |
| NCT01080222 | A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection | TERMINATED | PHASE2 | 2010-08 | 2013-11 | 2013-10 |
| NCT01117012 | Rollover Study of VX-770 in Cystic Fibrosis Subjects | COMPLETED | PHASE3 | 2010-07 | 2014-05 | 2014-05 |
| NCT01144936 | Study of VX-985 in Subjects With Chronic Hepatitis C | COMPLETED | PHASE1 | 2010-06 | 2010-10 | 2010-10 |
| NCT01153542 | Study of VX-770 on Desipramine | COMPLETED | PHASE1 | 2010-06 | 2010-08 | 2010-08 |
| NCT01052194 | A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis | COMPLETED | PHASE2 | 2010-02 | 2011-07 | 2011-07 |
| NCT01060566 | Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770 | COMPLETED | PHASE1 | 2010-02 | 2010-04 | 2010-03 |
| NCT01048255 | Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy | COMPLETED | PHASE2 | 2010-01 | 2010-11 | 2010-11 |
| NCT01038167 | A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults | COMPLETED | PHASE1 | 2010-01 | 2010-04 | 2010-04 |
| NCT01018368 | Study of VX-770 and Rifampin in Healthy Male Subjects | COMPLETED | PHASE1 | 2009-11 | 2010-03 | 2010-03 |
| NCT00983853 | Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV | COMPLETED | PHASE2 | 2009-10 | | 2012-03 |
| NCT00953706 | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation | TERMINATED | PHASE2 | 2009-09 | 2013-05 | 2010-07 |
| NCT00966602 | Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects | COMPLETED | PHASE1 | 2009-09 | 2009-12 | 2009-12 |
| NCT00909727 | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation | COMPLETED | PHASE3 | 2009-08 | 2011-04 | 2010-11 |
| NCT00958152 | Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects | COMPLETED | PHASE1 | 2009-08 | 2010-01 | 2010-01 |
| NCT00909532 | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation | COMPLETED | PHASE3 | 2009-06 | 2012-11 | 2010-07 |
| NCT00911963 | Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection | COMPLETED | PHASE1, PHASE2 | 2009-04 | 2012-09 | 2012-09 |
| NCT00923728 | A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors | WITHDRAWN | NA | 2009-04 | 2010-03 | 2010-03 |
| NCT00865904 | Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation | COMPLETED | PHASE2 | 2009-03 | 2009-12 | 2009-12 |
| NCT00758043 | A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response | COMPLETED | PHASE3 | 2008-10 | 2010-07 | 2010-06 |
| NCT00789126 | Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects | COMPLETED | PHASE1 | 2008-10 | | |
| NCT00627926 | A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) | COMPLETED | PHASE3 | 2008-03 | 2010-05 | 2010-05 |
| NCT00623649 | Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection | COMPLETED | PHASE1 | 2007-11 | 2008-10 | 2008-10 |
| NCT00535847 | A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy | COMPLETED | PHASE2 | 2007-10 | 2010-02 | 2010-02 |
| NCT00509210 | Study of Telaprevir in Subjects With Hepatic Impairment | COMPLETED | PHASE1 | 2007-09 | 2008-06 | 2008-06 |
| NCT00493441 | AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer | TERMINATED | PHASE2 | 2007-06 | 2009-12 | 2009-12 |
| NCT00457821 | Safety Study of Ivacaftor in Subjects With Cystic Fibrosis | COMPLETED | PHASE2 | 2007-05 | 2008-08 | 2008-08 |
| NCT00420784 | A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) | COMPLETED | PHASE2 | 2007-02 | 2009-04 | 2008-12 |
| NCT00395577 | A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702 | COMPLETED | PHASE2 | 2006-11 | 2007-07 | |
| NCT00389298 | A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection. | COMPLETED | PHASE1, PHASE2 | 2006-10 | 2007-06 | |
| NCT00372385 | Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C | COMPLETED | PHASE2 | 2006-08 | 2008-06 | 2008-05 |
| NCT00336479 | Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C | COMPLETED | PHASE2 | 2006-06 | 2008-02 | 2008-02 |
| NCT00273936 | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | COMPLETED | PHASE1 | 2006-01 | | |
| NCT00262483 | Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C | COMPLETED | PHASE2 | 2005-12 | 2006-04 | |
| NCT00251199 | VX-950 and Peginterferon for Hepatitis C | COMPLETED | PHASE1 | 2005-10 | 2006-03 | |
| NCT00205478 | Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702 | COMPLETED | PHASE2 | 2005-06 | 2006-02 | |
| NCT00500812 | A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries | COMPLETED | PHASE1, PHASE2 | 2005-02 | 2009-02 | 2008-12 |
| NCT00205465 | Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 | COMPLETED | PHASE2 | 2004-12 | 2005-09 | |
| NCT00088504 | Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C | COMPLETED | PHASE2 | 2004-07 | 2006-10 | |
| NCT00003847 | VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer | TERMINATED | PHASE2 | 1998-12 | | 2001-02 |